On Wednesday, Shares of Micron Technology, Inc. (NASDAQ:MU), gained 1.19% to $27.19.
On April 27, Micron Technology declared that it intends to offer, subject to market and other considerations, $500 million aggregate principal amount of senior notes due 2024 and $500 million aggregate principal amount of senior notes due 2026 through an offering to qualified institutional buyers following Rule 144A under the Securities Act of 1933, as amended and outside the United States to non-U.S. persons following Regulation S under the Securities Act.
The interest rate, redemption provisions and other terms of the Notes will be determined by negotiations between Micron and the initial purchasers.
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
Shares of The Kroger Co. (NYSE:KR), inclined 0.11% to $71.23, during its last trading session.
The Kroger, declared that Rodney McMullen, Kroger’s chairman and CEO, and Mike Schlotman, Kroger’s senior vice president and CFO, will address investors at the BMO Capital Markets Farm to Market Conference in New York on Wednesday, May 20, 2015 at 11:00 am (ET).
The Kroger Co., together with its auxiliaries, operates as a retailer in the United States and internationally. It also manufactures and processes food for sale in its supermarkets. The company operates retail food and drug stores, multi-department stores, jewelry stores, and convenience stores.
At the end of Wednesday’s trade, Shares of Medtronic plc (NYSE:MDT), lost -0.45% to $74.86.
Medtronic, declared the Arctic Front Advance® ST Cryoablation Catheter has received U.S. Food and Drug Administration (FDA) approval for the treatment of patients with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation. In Europe, where the Cryoballoon has a broader indication, Arctic Front Advance ST Cryoballoon has received CE (Conformité Européenne) Mark for the treatment of patients with atrial fibrillation. An integral part of the Arctic Front Advance® System, the third-generation cryoballoon has a 40 percent shorter tip than the previous generation, designed to assist physicians visualize ablation success in real-time with the Achieve® Mapping Catheter, in addition to allow raised maneuverability for accessing some pulmonary vein anatomies.
The Arctic Front Advance ST Cryoballoon is used in a minimally invasive procedure to isolate the pulmonary veins, which are a source of erratic electrical signals that cause atrial fibrillation. The device uses coolant rather than heat (radiofrequency). Cryoballoon technology is associated with shorter procedure times than point-by-point radiofrequency ablation1, 2, and better treatment outcomes than drug therapies on the market. The Arctic Front Advance System has been shown to improve quality of life for patients and significantly reduce paroxysmal (sporadic) atrial fibrillation symptoms, with patients experiencing reduction in atrial fibrillation episodes, palpitations, fatigue, rapid heartbeat, swelling, and syncope4, and has become a widely adopted treatment for atrial fibrillation.
Medtronic plc, a healthcare solutions company, provides medical technologies, services, and solutions worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group.
Finally, Fibrocell Science, Inc. (NASDAQ:FCSC), ended its last trade with 14.89% surge, and closed at $4.09.
Fibrocell Science, declared that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for Fibrocell’s lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and declared by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa (DEB), which comprises RDEB.
“We are happy that the FDA has granted our request to designate FCX-007 for the treatment of RDEB as a drug for a rare pediatric disease,” said David Pernock, Chairman and Chief Executive Officer of Fibrocell. “FCX-007 may offer RDEB patients and their families the first therapy to treat the underlying cause of the disease, bringing hope and relief to what is recently a painful, disabling and often fatal congenital disorder.
Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company, through its proprietary autologous fibroblast technology, develops azficel-T, which is in Phase II clinical trials for the treatment of vocal cord scarring and restrictive burn scarring.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
